Ferroptosis, necroptosis, and pyroptosis in the tumor microenvironment: Perspectives for immunotherapy of SCLC

X Niu, L Chen, Y Li, Z Hu, F He - Seminars in Cancer Biology, 2022 - Elsevier
Small cell lung cancer (SCLC) is an aggressive form of lung cancer characterized by dismal
prognosis. Although SCLC may initially respond well to platinum-based chemotherapy, it …

A review on CRISPR/Cas: a versatile tool for cancer screening, diagnosis, and clinic treatment

X Yang, B Zhang - Functional & Integrative Genomics, 2023 - Springer
Cancer is one of the leading causes of death worldwide and it has the trend of increase
incidence. However, in the past decades, as quickly developed new technologies and …

KDM6A epigenetically regulates subtype plasticity in small cell lung cancer

L Duplaquet, Y Li, MA Booker, Y Xie, SN Olsen… - Nature Cell …, 2023 - nature.com
Small cell lung cancer (SCLC) exists broadly in four molecular subtypes: ASCL1,
NEUROD1, POU2F3 and Inflammatory. Initially, SCLC subtypes were thought to be mutually …

Inhibition of LSD1 with bomedemstat sensitizes small cell lung cancer to immune checkpoint blockade and T-cell killing

JB Hiatt, H Sandborg, SM Garrison, HU Arnold… - Clinical Cancer …, 2022 - AACR
Purpose: The addition of immune checkpoint blockade (ICB) to platinum/etoposide
chemotherapy changed the standard of care for small cell lung cancer (SCLC) treatment …

[HTML][HTML] Targeting the Notch signaling pathway and the Notch ligand, DLL3, in small cell lung cancer

H Zhang, Y Yang, X Li, X Yuan, Q Chu - Biomedicine & Pharmacotherapy, 2023 - Elsevier
Small cell lung cancer (SCLC) is a highly aggressive and poorly differentiated cancer with
high-grade neuroendocrine (NE) features, accounting for approximately 15% of all lung …

Stimulation of cGAS-STING pathway as a challenge in the treatment of small cell lung cancer: a feasible strategy?

G Miglietta, M Russo, G Capranico… - British Journal of Cancer, 2024 - nature.com
Lung cancer has a significant incidence among the population and, unfortunately, has an
unfavourable prognosis in most cases. The World Health Organization (WHO) classifies lung …

Molecular phenotyping of small cell lung cancer using targeted cfDNA profiling of transcriptional regulatory regions

JB Hiatt, AL Doebley, HU Arnold, M Adil… - Science …, 2024 - science.org
We report an approach for cancer phenotyping based on targeted sequencing of cell-free
DNA (cfDNA) for small cell lung cancer (SCLC). In SCLC, differential activation of …

Single-cell and spatial proteo-transcriptomic profiling reveals immune infiltration heterogeneity associated with neuroendocrine features in small cell lung cancer

Y Jin, Y Wu, A Reuben, L Zhu, CM Gay, Q Wu, X Zhou… - Cell Discovery, 2024 - nature.com
Small cell lung cancer (SCLC) is an aggressive pulmonary neuroendocrine malignancy
featured by cold tumor immune microenvironment (TIME), limited benefit from …

[HTML][HTML] Aurora A kinase inhibition induces accumulation of SCLC tumor cells in mitosis with restored interferon signaling to increase response to PD-L1

Y Li, NR Mahadevan, L Duplaquet, D Hong… - Cell Reports …, 2023 - cell.com
Despite small cell lung cancers (SCLCs) having a high mutational burden, programmed
death-ligand 1 (PD-L1) immunotherapy only modestly increases survival. A subset of SCLCs …

Genetically-engineered mouse models of small cell lung cancer: the next generation

MG Oser, D MacPherson, TG Oliver, J Sage, KS Park - Oncogene, 2024 - nature.com
Small cell lung cancer (SCLC) remains the most fatal form of lung cancer, with patients in
dire need of new and effective therapeutic approaches. Modeling SCLC in an …